We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.87B
1-Year Est. Return 205.24%
This Fund
S&P 500
This Quarter Est. Return
+8.67%
1 Year Est. Return
+205.24%
3 Year Est. Return
+440.18%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.15B
AUM Growth
-$198M
Cap. Flow
-$346M
Cap. Flow %
-10.98%
Top 10 Hldgs %
41.12%
Holding
79
New
11
Increased
20
Reduced
24
Closed
8

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$70.4M
2
MBX
MBX Biosciences
MBX
+$69M
3
IMVT icon
Immunovant
IMVT
+$43.2M
4
ORKA
Oruka Therapeutics
ORKA
+$43M
5
GH icon
Guardant Health
GH
+$42.5M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$180M
2
INSM icon
Insmed
INSM
+$134M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$122M
4
AXSM icon
Axsome Therapeutics
AXSM
+$86.9M
5
TVTX icon
Travere Therapeutics
TVTX
+$71.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.35%
2 Miscellaneous 0.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HLVX
76
DELISTED
HilleVax
HLVX
– –
-1,832,652
Closed -$26.5M
INSM icon
77
Insmed
INSM
$26.8B
– –
-2,000,000
Closed -$134M
PRAX icon
78
Praxis Precision Medicines
PRAX
$8.75B
– –
-389,546
Closed -$16.1M
RPTX
79
DELISTED
Repare Therapeutics
RPTX
– –
-904,261
Closed -$2.98M
1 2 3
4

Similar funds

PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
NP
NorthRock Partners Minneapolis, Minnesota $6.89B AUM 19.83% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $6.92B AUM 24.7% 1-Year Est. Return
RCWMU
Rothschild & Co Wealth Management (UK) London, United Kingdom $6.93B AUM 1.4% 1-Year Est. Return
CA
Cambridge Associates Boston, Massachusetts $6.93B AUM 17.96% 1-Year Est. Return
LIP
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return
CI
Cincinnati Insurance Fairfield, Ohio $6.94B AUM 20.24% 1-Year Est. Return

Deep Track Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Deep Track Capital held 79 positions worth $3.15B, down 5.9% from $3.35B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Deep Track Capital withdrew a net $346M in Q3 2024, closing 8 positions and reducing 24 holdings. Its most notable exit was Amgen, an estimated $180M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Deep Track Capital opened a new position in MBX Biosciences worth $78.4M.

  • Deep Track Capital's largest Q3 2024 buy was MBX Biosciences: 3,018,935 shares worth $78.4M.
  • Deep Track Capital added most to Apellis Pharmaceuticals in Q3 2024, an estimated $70.4M increase.
  • Deep Track Capital's biggest Q3 2024 reduction was Axsome Therapeutics, cutting an estimated $86.9M.
  • Deep Track Capital fully exited Amgen in Q3 2024, selling an estimated $180M.
  • Deep Track Capital's ten largest holdings make up 41% of its $3.15B portfolio in Q3 2024.
  • Deep Track Capital opened 11 new positions and closed 8 in Q3 2024.
  • Deep Track Capital's portfolio value fell 5.9% quarter-over-quarter to $3.15B.

Based on Deep Track Capital's 13F filing for Q3 2024, filed 14 Nov 2024.